Please login to the form below

Not currently logged in

J&J’s targeted bladder cancer treatment gets US approval

Balversa is first FGFR inhibitor

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin pensInsulin price nearly tripled between 2002 and 2013

NICE says no to Novartis’ Kisqali combo in breast cancer

NICE (National for Health and Clinical Excellence)Double blow after Lilly rival recommended

Lynparza set for further expansion with EU approval in breast cancer

LynparzaCompanies have prostate cancer and pancreatic cancer in their sights

UniQure gets speedy US review for Huntington’s gene therapy

UniqurePioneer gaining momentum again

Celgene files luspatercept ahead of key merger vote

CelgeneAnalysts predict peak revenues of $2bn

Teva’s migraine injection approved in Europe

AjovyThird anti-CGRP treatment to hit the market

AVEO warns EU approval of Fotivda could be at risk

ema1Concerns arose with overall survival data

Brexit‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’

Brexit means pharma must review its intellectual property rights across Europe

Latest regulatory appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...